{"eventGroups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"EG000","otherNumAffected":1,"otherNumAtRisk":65,"seriousNumAffected":0,"seriousNumAtRisk":65,"title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"EG001","otherNumAffected":4,"otherNumAtRisk":70,"seriousNumAffected":0,"seriousNumAtRisk":70,"title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"EG002","otherNumAffected":2,"otherNumAtRisk":65,"seriousNumAffected":0,"seriousNumAtRisk":65,"title":"Mirabegron 100 mg"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v9.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":65},{"groupId":"EG001","numAffected":4,"numAtRisk":70},{"groupId":"EG002","numAffected":2,"numAtRisk":65}],"term":"Nasopharyngitis"}],"timeFrame":"From first dose to within 30 days after last dose of double blind study medication (up to 16 weeks)."}